Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2019-07-03 Director's Dealing
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2019-07-03 English
4
Director's Dealing
2019-07-03 English
4
Director's Dealing
2019-06-28 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 26, 2019, reporting changes in the company's executive management. It details the departure of the current CEO, the appointment of the CFO as the new CEO, employment agreements, and related arrangements. The content focuses on board and senior management changes rather than financial results, audit information, or other report types. Therefore, it fits the category of Board/Management Information (MANG). The document length and detail confirm it is not a brief announcement or a certification but a substantive report on management changes.
2019-06-27 English
4
Director's Dealing
2019-05-18 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 14, 2019, reporting the entry into a material definitive agreement (a collaboration and license agreement) and other related events. It includes a summary of the agreement terms, mentions a press release, and references that the full agreement will be filed as an exhibit to a future 10-Q. The document is a current report on material events and does not contain financial statements or detailed financial analysis. It is not an earnings release, annual report, or interim report. It is a regulatory filing reporting a material event as required by the SEC under the Exchange Act. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-05-15 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.